Health Condition 1: null- TB-HIV Co-infection
Conditions
Interventions
Intervention1: Rosuvastatin 10 mg once a day: One arm of the study will be given rosuvastatin along with ATT and ART
Control Intervention1: Placebo - folic acid: The second arm will be administered pl
Sponsors
Department of Internal Medicine
Eligibility
Inclusion criteria
Inclusion criteria: 1.HIV-TB co-infected patients who are being started on ATT-ART 2. Age > 18 yrs
Exclusion criteria
Exclusion criteria: a) Patients already on statins b) Patients already on ART / ATT c) Patients on other lipid lowering agents d) Patients who have abnormal LFT at baseline e) Patients with clinical evidence of myopathy f) Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)Weight gain at 6 months 2)Percentage of patients with more than 10 percent increase in CD4 count from baseline 3)To study the change in Vit D levels at 8 weeks, 6 months and 12 months Timepoint: 1)Weight gain at 6 months 2)Percentage of patients with more than 10 percent increase in CD4 count from baseline at 8 weeks and 6 months 3)To study the change in Vit D levels at 8 weeks, 6 months and 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Apart from weight gain and rise in CD4 count; statistical analysis about sputum conversion rates, decrease in viral load, ESR, hsCRP and radiological resolution will be done. An analysis of how rapid there is clinical improvement, sputum conversion, improvement in CD4 count and suppression of inflammatory markers & viral load will also be done.Timepoint: 3,6 and 12 months | — |
Countries
India
Contacts
Public ContactGroup Captain V K Sashindran
Armed Forces Medical College
Outcome results
None listed